vasospasm inhibitors
A vasospasm inhibitor using synergistic combinations of specific compounds like 2,5-dihydroxybenzoic acid and caffeoylquinic acids selectively inhibits abnormal vascular contractions, addressing the challenge of differentiating between normal and abnormal contractions and providing therapeutic benefits for vasospasm-related diseases.
Patent Information
- Application Number
- JP2024163902
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2025-09-26
- Estimated Expiration
- 2044-09-20
AI Technical Summary
Existing vasospasm inhibitors do not effectively differentiate between normal and abnormal vascular contractions, leading to potential adverse effects on normal vascular functions, and there is a need for substances that can specifically inhibit abnormal vascular contractions without affecting normal vascular functions.
A vasospasm inhibitor containing compounds such as 2,5-dihydroxybenzoic acid, trans-3-caffeoylquinic acid, trans-4-caffeoylquinic acid, trans-5-caffeoylquinic acid, and 2-hydroxybenzoic acid or their salts, which are synergistically combined to enhance antivasospasm activity, providing selective inhibition of abnormal vascular contractions.
The inhibitor effectively prevents and inhibits abnormal vascular contractions, offering therapeutic benefits for conditions like cerebral infarction, myocardial infarction, and angina pectoris, and can be used as pharmaceuticals or functional foods to prevent or treat vasospasm-related diseases.